Literature DB >> 17395120

Hypertension in pregnancy.

Tiina Podymow1, Phyllis August.   

Abstract

Hypertensive disorders of pregnancy are the most common medical disorders of pregnancy and are associated with increased maternal and perinatal risks. The pathophysiology, diagnosis, and treatment are herein reviewed for chronic hypertension, preeclampsia, gestational hypertension, and severe hypertension. The benefits and risks of treating mild, moderate, and severe hypertension are discussed. A variety of oral and parenteral therapies are approved for the treatment of hypertension in pregnancy; methyldopa, labetalol, and nifedipine have been used safely in pregnancy, as has hydrochlorothiazide in those already taking this medication before conception. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are contraindicated in pregnancy because of adverse fetal effects, and atenolol should be avoided due to concerns with fetal growth. Severe hypertension >160/110 mmHg may require parenteral therapy, and treatment with intravenous labetalol now supplants the use of hydralazine. Women may remain hypertensive for a period postpartum and require treatment for a short interval. Early or severe preeclampsia warrants workup postpartum for secondary causes. Pregnancy induced hypertension or preeclampsia are emerging as risk factors for future cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17395120     DOI: 10.1053/j.ackd.2007.01.008

Source DB:  PubMed          Journal:  Adv Chronic Kidney Dis        ISSN: 1548-5595            Impact factor:   3.620


  22 in total

1.  Characterisation of peripartum cardiomyopathy by cardiac magnetic resonance imaging.

Authors:  Ntobeko B A Ntusi; Ashley Chin
Journal:  Eur Radiol       Date:  2008-12-16       Impact factor: 5.315

Review 2.  Secondary Hypertension in Pregnancy.

Authors:  Line Malha; Phyllis August
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

3.  Effects of pregnancy, hypertension and nitric oxide inhibition on rat uterine artery myogenic reactivity.

Authors:  Carolyn Barron; Maurizio Mandala; George Osol
Journal:  J Vasc Res       Date:  2010-04-30       Impact factor: 1.934

4.  Angiogenic imbalance and diminished matrix metalloproteinase-2 and -9 underlie regional decreases in uteroplacental vascularization and feto-placental growth in hypertensive pregnancy.

Authors:  Carlos A Dias-Junior; Juanjuan Chen; Ning Cui; Charles L Chiang; Minglin Zhu; Zongli Ren; Jose S Possomato-Vieira; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2017-09-11       Impact factor: 5.858

5.  Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.

Authors:  Zongli Ren; Ning Cui; Minglin Zhu; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-03-23       Impact factor: 4.733

6.  Kidney disease in childhood-onset diabetes.

Authors:  Robert G Nelson
Journal:  Am J Kidney Dis       Date:  2008-08-03       Impact factor: 8.860

Review 7.  Optimal use of beta-blockers in high-risk hypertension: a guide to dosing equivalence.

Authors:  Janet B McGill
Journal:  Vasc Health Risk Manag       Date:  2010-06-01

8.  Long-term neurodevelopment of children exposed in utero to ciclosporin after maternal renal transplant.

Authors:  Irena Nulman; Michael Sgro; Maru Barrera; David Chitayat; John Cairney; Gideon Koren
Journal:  Paediatr Drugs       Date:  2010-04-01       Impact factor: 3.022

Review 9.  Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection.

Authors:  Amret Hawfield; Barry I Freedman
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-11-04

Review 10.  Pregnancy after kidney transplantation.

Authors:  Dianne B McKay; Michelle A Josephson
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.